Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial

Toby M Maher, Mark J Hamblin, Won-Il Choi, Amy Hajari Case, Ioannis P Tomos, Argyrios E Tzouvelekis, Jessica E Shore, Miguel A Bergna, David Golod, Eric Elenko, Yanqiong Zhang, Camilla S Graham, Jin Woo Song, Tejaswini Kulkarni, and the ELEVATE IPF Investigators · 2026

Read Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial by Toby M Maher, Mark J Hamblin, Won-Il Choi, Amy Hajari Case, Ioannis P Tomos, Argyrios E Tzouvelekis, Jessica E Shore, Miguel A Bergna, David Golod, Eric Elenko, Yanqiong Zhang, Camilla S Graham, Jin Woo Song, Tejaswini Kulkarni, and the ELEVATE IPF Investigators (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13424664.txt.

Description

Maher and the ELEVATE IPF Investigators report a phase 2b trial of a reformulated lung drug. Their 2026 paper tests deupirfenidone, a chemically modified version of pirfenidone designed to keep its benefits with a kinder profile, in idiopathic pulmonary fibrosis, a progressive scarring lung disease. A total of 257 patients were randomised to two deupirfenidone doses, standard pirfenidone, or placebo for 26 weeks.

Lung capacity, measured as forced vital capacity, fell by about 111 millilitres on placebo but only about 48 millilitres across the combined deupirfenidone arms. The higher dose alone beat placebo by an adjusted margin of about 91 millilitres in the conventional analysis. Gastrointestinal side effects were the most common in every active arm. The authors conclude deupirfenidone slowed disease progression over the trial period.

Catalog record

CREATORToby M Maher, Mark J Hamblin, Won-Il Choi, Amy Hajari Case, Ioannis P Tomos, Argyrios E Tzouvelekis, Jessica E Shore, Miguel A Bergna, David Golod, Eric Elenko, Yanqiong Zhang, Camilla S Graham, Jin Woo Song, Tejaswini Kulkarni, and the ELEVATE IPF Investigators
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13424664

Browse the full library · About the Tower of Babel